Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Molecular Ecology Resources|October 12, 2021
Chromosome-level genome assembly reveals genomic architecture of northern range expansion in the mountain pine beetle, Dendroctonus ponderosae Hopkins (Coleoptera: Curculionidae)Christopher I Keeling, Erin O Campbell, Philip D Batista, et al.
Anesthesiology|May 29, 2012
Identification of two mutations (F758W and F758Y) in the N-methyl-D-aspartate receptor glycine-binding site that selectively prevent competitive inhibition by xenon without affecting glycine bindingScott P Armstrong, Paul J Banks, Thomas J W McKitrick, et al.
The Journal of Antibiotics|January 26, 1999
Novel erythromycins from a recombinant Saccharopolyspora erythraea strain NRRL 2338 pIG1. I. Fermentation, isolation and biological activityM S Pacey, J P Dirlam, R W Geldart, et al.
European Urology|September 15, 2015
A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal CancerThomas Powles, Matthew Wheater, Omar Din, et al.
Ecology and Evolution|March 12, 2024
An interspecific foraging association with polar bears increases foraging opportunities for avian predators in a declining Arctic seabird colonyAndrew F Barnas, Cassandra A B Simone, Erica A Geldart, et al.
European Urology|December 4, 2014
SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinomaThomas Geldart, John Chester, Angela Casbard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2016
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLCEdurne Arriola, Matthew Wheater, Ian Galea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2015
Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I studyPeter Johnson, Ruth Challis, Ferdousi Chowdhury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)T Powles, J Brown, J Larkin, et al.
British Journal of Cancer|December 5, 2024
Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapySanjay Popat, Adam Januszewski, Mary O'Brien, et al.
Pageof 7